Skip to content
OpenCapital
Get started

West Pharmaceutical Services WST Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

AptarGroup logo
AptarGroupATR
-$230.34M-70.9%
Sonoco Products logo
Sonoco ProductsSON
$302.21M+921%
Trimas logo
TrimasTRS
-$132.34M-540%
UFP Technologies logo
UFP TechnologiesUFPT
-$1.62M+84.9%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-$256K—
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$23.72B+30.4%
Enterprise value$23.6B+31.2%
P/E42×+4.7×
P/S7.1×+1.0×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: West Pharmaceutical Services’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's cash provided by (used in) financing activity, including discontinued operation?
West Pharmaceutical Services (WST) reported cash provided by (used in) financing activity, including discontinued operation of -$164.8M in Q2 2026.
How has West Pharmaceutical Services's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
West Pharmaceutical Services's cash provided by (used in) financing activity, including discontinued operation decreased by 1006.0% year-over-year, from -$14.9M to -$164.8M.
What is the long-term trend for West Pharmaceutical Services's cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), West Pharmaceutical Services's cash provided by (used in) financing activity, including discontinued operation has grown at a 2.4% compound annual growth rate (CAGR), from -$168.4M to -$185.1M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.